Ionis Cuts TRYNGOLZA Guidance After Third-Quarter Results

Ionis Pharmaceuticals cut its full-year 2026 sales guidance for TRYNGOLZA after a slower-than-expected U.S. launch, the company said on Nov. 9, 2026. A law-firm securities investigation followed the guidance revision, raising questions about the drug’s near-term commercial outlook.

Revenue Growth and Rising Expenses

Ionis reported total revenue of $243 million for the quarter ended Sept. 30, 2026, up from $157 million a year earlier. The company posted a GAAP net loss of $110 million, narrower than the $129 million loss in the prior-year quarter. Operating expenses increased to $373 million from $317 million.

Collaborative-agreement revenue rose to $103 million from $31 million a year earlier. Product sales included DAWNZERA net sales of $37 million in the quarter and $79 million for the first nine months of 2026. ZANVASTRO generated $2 million in the quarter.

TRYNGOLZA Guidance Cut and Securities Probe

U.S. net product sales for TRYNGOLZA were $9 million in Q3 and $41 million for the first nine months of 2026. Ionis reduced full-year TRYNGOLZA net-product-sales guidance to approximately $50 million from $100 million–$110 million, citing a more gradual launch ramp as it establishes a new treatment paradigm for severe hypertriglyceridemia. Management said it remained confident in TRYNGOLZA’s longer-term revenue potential.

The company described TRYNGOLZA, also known as olezarsen, as FDA-approved as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, defined as triglycerides of at least 500 mg/dL. The European Medicines Agency committee issued a positive opinion for severe hypertriglyceridemia involving fasting triglycerides of at least 880 mg/dL (10 mmol/L), with a final European decision expected in Q4 2026. The company noted that 2026 included three approvals for first-in-class medicines, two of them Ionis-owned.

Ionis reaffirmed overall 2026 guidance for total revenue of $875 million–$900 million, DAWNZERA net-product-sales guidance of $110 million–$120 million, and non-GAAP operating-loss guidance of $425 million–$475 million. It said year-end cash, cash equivalents, and short-term investments would exceed $1.6 billion.

Following the TRYNGOLZA guidance reduction, a law firm announced an investigation into potential securities claims, stating the disclosures raise questions about whether Ionis adequately disclosed adverse sales trends and commercialization challenges known to management during the quarter. The announcement does not establish wrongdoing.

Available materials indicate management discussed delaying its sustained-positive-cash-flow target by one year.

Together, the reduced TRYNGOLZA sales outlook and the law-firm announcement have become the immediate factors reframing Ionis’s near-term commercial and disclosure risk, despite the company’s year-over-year revenue growth and narrower GAAP loss in the quarter.